A progressive neurological disease, Alzheimer's disease (AD) is identified by cognitive decline and memory loss. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease (AD) is the most common type of dementia and represents a significant global health problem due to its profound impact on patients' quality of life and the heavy burden it places on health care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
27/100
Alzheimer's disease (AD) is a neurological condition that worsens over time and is characterised by tau tangles and amyloid plaques. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dysregulated ferritinophagy-mediated ferroptosis is a pivotal AD pathogenic target. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Introdução: O sequenciamento de nova geração (NGS) tem revolucionado a compreensão da doença de Alzheimer (DA), desvendando biomarcadores genéticos e transcriptômicos que aprimoram a estrutura ATN (beta-amiloide, Tau, neurodegeneração). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease (AD) is a multi-factorial neurodegenerative disease that is characterized by accumulation of amyloid-beta (Aβ), protein aggregation and progressive neuronal dysfunction. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dysfunctional GAA results in widespread glycogen accumulation leading to muscle weakness, cardiovascular and breathing problems and premature death. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A Doença de Alzheimer (DA) é a principal causa de demência em idosos, causada pelo acúmulo de β-amiloide e emaranhados neurofibrilares no cérebro. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Objetivo: Objetivou-se sintetizar, em revisão narrativa, as evidências publicadas entre 2022–2025 sobre o potencial neuroprotetor dos análogos do GLP-1 na Doença de Alzheimer (DA). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Các bệnh lý như lao và Alzheimer đòi hỏi phát hiện sớm với độ nhạy cao để can thiệp kịp thời, tuy nhiên các kỹ thuật hiện nay như ELISA, PCR còn hạn chế về chi phí và độ nhạy. Những tiến bộ gần đây trong công nghệ nano cho thấy hạt nano vàng vỏ đồng kết hợp sinh phẩm tái tổ hợp (protein hoặc aptamer) có thể khuếch đại tín hiệu màu, mở ra triển vọng cho chẩn đoán sớm siêu nhạy. Bài tổng quan này phân tích cơ chế kỹ thuật xét nghiệm kháng nguyên bằng sự hình thành vỏ nano đồng trên hạt vàng, trong đó ion Cu²⁺ được khử bởi natri ascorbate trên bề mặt AuNPs với vai trò ổn định của polyethylenimine, tạo cấu trúc Au-Cu đa giác giúp tăng cường tín hiệu plasmon. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Las enfermedades neurodegenerativas representan un importante problema de salud pública debido a su creciente prevalencia y al carácter progresivo e irreversible del daño neuronal que producen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Introdução: Com o aumento da expectativa de vida e do percentual de idosos no país, também está crescendo a taxa de doenças neurodegenerativas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
27/100
BSA-polymer conjugates displayed enhanced resistance to proteolytic degradation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment in the elderly causes a decrease in the ability to do various things related to thinking and remembering. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Agents currently in use against human immunodeficiency virus (HIV) infection, including the prospects of a vaccine, have focused primarily on destroying or disabling the virus. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer’s disease is the leading cause of dementia and represents a growing global health challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
27/100
Dementia encompasses a group of progressive neurodegenerative disorders marked by cognitive, behavioural, and functional decline, underpinned by complex neurobiological processes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eligible studies used many study designs with different sample sizes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Advance care planning aims to allow individuals to discuss their goals and preferences for future medical and nursing care with family members and medical personnel in advance when they still have decision-making ability, so that individuals can receive medical care that meets their preferences when they lose their decision-making ability. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Riverside Health has developed a new palliative care pathway to serve as an innovative standard of person-centered care for persons living with dementia (PLWD) and their care partners. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive condition that gradually impairs cognitive function, memory, and daily living skills. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Gaining competitive advantage in retailing requires knowledge of the attributes consumers use to evaluate stores and an understanding of why these attributes are important. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is thought that every elderly has at least one dermatological problem. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
(1) GARS-AIRS-GART is an important candidate gene in studies of Down syndrome (DS)-related Alzheimer's disease (AD), due to its chromosomal localization (21q22.1) in the Down syndrome critical region, involvement in de novo purine biosynthesis, and over-expression in DS brain. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →